Table 1.
Characteristics of axSpA, pSS patients and healthy donors.
| axSpA | pSS | HD | |
|---|---|---|---|
| Number of patients | 45 | 20 | 30 |
| Age (years) | 49 ± 13 | 51 ± 12 | 48 ± 21 |
| Male gender (%) | 62 | 20 | 63 |
| Symptom duration (years) | 23 (15) | 11 (9) | |
| ESR (mm/hr) | 13 (15.8) | 20 (15.5) | |
| CRP (mg/L) | 2.9 (5.2) | 1.5 (3.3) | |
| IgG (g/L) | 14.1 (5.1) | ||
| History of biologic DMARD use (%) | 42.2 | 30 | |
| AxSpA specific features: | |||
| AS (%) | 80 | ||
| HLA-B27 positive (%) | 93 | ||
| ASDAS | 2.5 ± 1.0 | ||
| BASDAI | 4.3 ± 2.4 | ||
| History of: | |||
| Uveitis | 16 (36) | ||
| Inflammatory bowel disease | 4 (9) | ||
| Psoriatic arthritis | 3 (7) | ||
| >1 ESM | 19 (37) | ||
| History of: | 13 (29) | ||
| Peripheral arthritis | 6 (13) | ||
| Enthesitis | 5 (11) | ||
| Dactylitis | 3 (7) | ||
| ≥1 PM | 13 (29) | ||
| pSS specific features: | |||
| ESSPRI | 6.3 ± 2.2 | ||
| ESSDAI | 3 (6) | ||
| Anti-Ro/SSA positive (%) | 70 | ||
| Anti-La/SSB positive (%) | 50 | ||
| Rheumatoid factor positive (%) | 60 | ||
| Schirmer’s test (mm/5min) | 3.0 (12.0) | ||
| Ocular staining score | 2.0 (5.0) | ||
| UWSF (mL/min) | 0.1 (0.3) | ||
| Focus score | 2.8 ± 2.0 |
Data are presented as number of patients (%), mean ± SD or median (IQR); AS, Ankylosing spondylitis; HLA-B27, Human leukocyte antigen B27; DMARD, Disease modifying antirheumatic drugs; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; ASDAS, Ankylosing Spondylitis Disease Activity Score; ESM, extra skeletal-manifestations; PM, peripheral manifestations; ESSPRI, EULAR Sjögren’s Syndrome Patient Reported Index; ESSDAI, EULAR Sjögren’s syndrome disease activity index; Anti-SSA, Anti-Sjögren’s-syndrome-related antigen A autoantibodies; Anti-SSB, Anti-Sjögren’s-syndrome-related antigen B autoantibodies; UWSF, unstimulated whole saliva flow; Focus score in parotid gland tissue.